Open Payments

SUTTER SANTA ROSA REGIONAL HOSPITAL

Type
Teaching hospital
Where
Santa Rosa, CA
Medicare CCN
050291
Received
$270,032 in 44 records, 2020 ($2,500 general, $267,532 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment1$2,500
2020Research payment43$267,532

By company

CompanyRecordsAmountYears
ABBVIE INC.25$212,4302020
UCB SA12$39,0432020
MicroVention, Inc.3$9,6002020
Celgene Corporation2$4,3752020
Boston Scientific Corporation1$2,5002020
Partner Therapeutics, Inc.1$2,0842020

By nature of payment

NatureRecordsAmount
Research payment43$267,532
Charitable Contribution1$2,500

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-04ABBVIE INC.$4,031Research paymentCash or cash equivalentM18-9182020
2020-12-04ABBVIE INC.$2,990Research paymentCash or cash equivalentM14-3972020
2020-11-30Partner Therapeutics, Inc.$2,084Research paymentIn-kind items and servicesLEUKINE Drug, HematologyILeukPulm2020
2020-11-12ABBVIE INC.$20,514Research paymentCash or cash equivalentM18-9182020
2020-11-12UCB SA$16,292Research paymentCash or cash equivalentA RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU2020
2020-11-05ABBVIE INC.$6,511Research paymentCash or cash equivalentM14-3972020
2020-10-29MicroVention, Inc.$2,800Research paymentCash or cash equivalentRUPTURED ANEURYSMS TREATED WITH HYDROGEL COILS (RAGE)2020
2020-10-19UCB SA$4,824Research paymentCash or cash equivalentPhase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE2020
2020-10-06ABBVIE INC.$3,843Research paymentCash or cash equivalentM18-9182020
2020-10-06ABBVIE INC.$209Research paymentCash or cash equivalentM14-3972020
2020-10-01UCB SA$2,170Research paymentCash or cash equivalentPhase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE2020
2020-09-24UCB SA$1,200Research paymentCash or cash equivalentPhase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE2020
2020-09-03ABBVIE INC.$3,295Research paymentCash or cash equivalentM14-3972020
2020-09-03ABBVIE INC.$3,034Research paymentCash or cash equivalentM18-9182020
2020-08-13UCB SA$2,203Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT 2020
2020-08-06ABBVIE INC.$888Research paymentCash or cash equivalentCREON Drug, ENDOCRINOLOGYP12-7922020
2020-08-05ABBVIE INC.$12,517Research paymentCash or cash equivalentM18-9182020
2020-08-05ABBVIE INC.$7,226Research paymentCash or cash equivalentM14-3972020
2020-08-03UCB SA$586Research paymentCash or cash equivalentPhase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE2020
2020-07-23UCB SA$540Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN2020
2020-07-23UCB SA$500Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN2020
2020-07-07ABBVIE INC.$2,263Research paymentCash or cash equivalentM18-9182020
2020-07-07ABBVIE INC.$1,271Research paymentCash or cash equivalentM14-3972020
2020-06-17MicroVention, Inc.$500Research paymentCash or cash equivalentRUPTURED ANEURYSMS TREATED WITH HYDROGEL COILS (RAGE)2020
2020-06-04ABBVIE INC.$22,655Research paymentCash or cash equivalentM18-9182020
2020-06-04ABBVIE INC.$9,029Research paymentCash or cash equivalentM14-3972020
2020-06-04UCB SA$4,111Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN2020
2020-06-04UCB SA$1,500Research paymentCash or cash equivalentPhase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE2020
2020-06-04UCB SA$1,200Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN2020
2020-05-13ABBVIE INC.$4,500Research paymentCash or cash equivalentM14-3972020
2020-05-01Celgene Corporation$1,000Research paymentCash or cash equivalentREBLOZYL Biological, HematologyA Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alph2020
2020-04-08Boston Scientific Corporation$2,500Charitable ContributionIn-kind items and servicesGeneral Therapies Device, General2020
2020-04-03ABBVIE INC.$15,811Research paymentCash or cash equivalentM18-9182020
2020-04-03ABBVIE INC.$10,507Research paymentCash or cash equivalentM14-3972020
2020-03-05ABBVIE INC.$5,543Research paymentCash or cash equivalentM14-3972020
2020-03-05ABBVIE INC.$4,653Research paymentCash or cash equivalentM18-9182020
2020-03-04ABBVIE INC.$9,000Research paymentCash or cash equivalentM14-3972020
2020-03-04ABBVIE INC.$1,500Research paymentCash or cash equivalentM18-9182020
2020-02-17Celgene Corporation$3,375Research paymentCash or cash equivalentRevlimid Drug, HematologyCelgene - Connect MDS/AML2020
2020-02-10UCB SA$3,915Research paymentIn-kind items and servicesA PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT 2020
2020-02-05ABBVIE INC.$27,990Research paymentCash or cash equivalentM18-9182020
2020-02-05ABBVIE INC.$10,055Research paymentCash or cash equivalentM14-3972020
2020-01-30MicroVention, Inc.$6,300Research paymentCash or cash equivalentRUPTURED ANEURYSMS TREATED WITH HYDROGEL COILS (RAGE)2020
2020-01-03ABBVIE INC.$22,584Research paymentCash or cash equivalentM14-3972020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Sonoma CountySanta Rosa city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Santa Rosa, CA, county Sonoma County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Santa Rosa, CA
County
Sonoma County, CA
State
California
Population B01003177,090485,04039,287,377
Population, 2020 census P1178,127488,86339,538,223
Median age B0100241.242.937.9
Under 18 B0100120.1%19.0%22.0%
65 and over B0100119.0%21.5%15.7%
Households B1100168,321190,99813,548,091
Foreign born B0500221.2%16.8%27.0%
Median household income B19013$99,060$104,674$99,122
Median family income B19113$120,944$126,900$113,346
Per capita income B19301$52,066$56,640$49,513
Poverty rate B170019.7%8.9%12.0%
Unemployment rate B230256.3%5.7%6.6%
Civilian labor force B2302596,710258,15520,068,466
Mean commute (minutes) B0801322.925.128.7
Bachelor's degree or higher B1500335.1%38.5%37.1%
Housing units B2500171,382207,69914,644,735
Owner-occupied B2500356.7%62.6%55.9%
Renters B2500343.3%37.4%44.1%
Median home value B25077$713,900$815,500$734,700
Median gross rent B25064$2,152$2,158$2,036
White, not Hispanic B0300248.7%57.9%33.8%
Black B030021.9%1.5%5.2%
Hispanic or Latino B0300237.4%30.0%40.2%
Asian B030026.3%4.3%15.3%
American Indian and Alaska Native B030020.3%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Rosa, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.